AKTX 8-K 2026-10-01
Akari Therapeutics Plc (AKTX) 8-K dated 2026-10-01 — accession 0001493152-26-045364.
Akari Therapeutics Plc (AKTX) is a biotechnology company listed on US.
Akari Therapeutics Plc filed a 8-K on 2026-10-01. Accession 0001493152-26-045364.
This 8-K covers: Director/officer change (Item 5.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported AKTX revenue for 2024-06-30 was $0. Net income was -$7.6M. AKTX currently screens at market cap $17.2M.
Not investment advice. The AKTX SEC hub lists recent forms. The stock page is the research view.